Key clinical point: First-line pembrolizumab provides durable long-term overall survival (OS) benefit, compared with that of chemotherapy, in patients with advanced nonsquamous NSCLC.
Major finding: Median OS at 3 years was 26.3 months with pembrolizumab versus 14.2 months with chemotherapy (hazard ratio, 0.65).
Study details: The open-label phase 3 KEYNOTE-024 study of 305 patients.
Disclosures: KEYNOTE-024 was funded by Merck Sharp & Dohme. Dr. Reck reported receiving personal fees/honoraria for consultancy and lectures from Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Merck Sharp & Dohme, MSD, Eli Lilly, Pfizer, AbbVie, Roche, and Novartis.
Reck M et al. WCLC 2019, Abstract OA14.01.